A tale of two approaches: Complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments

Carcinogenesis

Volumn 34, Issue 4, 2013, Pages 725-738

  Masui, Kenta ^a   Gini, Beatrice ^a   Wykosky, Jill ^a   Zanca, Ciro ^a   Mischel, Paul S ^a,b,c   Furnari, Frank B ^a,b,c   Cavenee, Webster K ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ANTHRACYCLINE; BRENTUXIMAB VEDOTIN; CAPECITABINE; CARMUSTINE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLIC ACID; GEMCITABINE; IRINOTECAN; ISOSORBIDE; LIPOSOME; METHOTREXATE; MONOCLONAL ANTIBODY; NAVITOCLAX; NUCLEOSIDE ANALOG; OXALIPLATIN; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VEDOTIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BILIARY TRACT CANCER; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DNA DAMAGE; DNA REPLICATION; DNA STRAND; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; EXCISION REPAIR; GENETIC POLYMORPHISM; GLIOBLASTOMA; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA CELL; MICROTUBULE; MOLECULARLY TARGETED THERAPY; PANCREAS CANCER; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; THERAPY RESISTANCE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84875920923     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt086     Document Type: Review

References (204)

1. Pui,C.H. et al. (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood, 120, 1165-1174.
2. Garraway,L.A. et al. (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov., 2, 214-226.
3. González-Neira,A. (2012) Pharmacogenetics of chemotherapy efficacy in breast cancer. Pharmacogenomics, 13, 677-690.
4. Gottesman,M.M. et al. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2, 48-58.
5. Chabner,B.A. et al. (2005) Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer, 5, 65-72.
6. Ettinger,D.S. et al.; NCCN (National Comprehensive Cancer Network). (2012) Non-small cell lung cancer. J. Natl. Compr. Canc. Netw., 10, 1236-1271.
7. Rose,P.G. et al.; Gynecologic Oncology Group. (2007) Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol., 25, 2804-2810.
8. Pectasides,D. et al. (2008) Chemotherapy for recurrent cervical cancer. Cancer Treat. Rev., 34, 603-613.
9. Cunningham,D. et al. (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 27, 5513-5518.
10. Hung,S.W. et al. (2012) Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett., 320, 138-149.
11. Valle,J. et al.; ABC-02 Trial Investigators. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med., 362, 1273-1281.
12. Barrett,D. et al. (2012) Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs, 14, 299-316.
13. Geyer,C.E. et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 355, 2733-2743.
14. Sternberg,C.N. et al. (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur. Urol., 63, 58-66.
15. Haller,D.G. et al. (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol., 29, 1465-1471.
16. Quinn,J.A. et al. (2009) Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol., 27, 1262-1267.
17. Ready,N. et al. (2011) Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in secondline non-small cell lung cancer. J. Thorac. Oncol., 6, 781-785.
18. Roberts,A.W. et al. (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol., 30, 488-496.
19. Danesi,R. et al. (2001) Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol. Sci., 22, 420-426.
20. Treat,J. et al. (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J. Natl. Cancer Inst., 82, 1706-1710.
21. Slingerland,M. et al. (2012) Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today, 17, 160-166.
22. Stathopoulos,G.P. et al. (2010) Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann. Oncol., 21, 2227-2232.
23. Batist,G. et al. (2009) Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res., 15, 692-700.
24. Younes,A. et al. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol., 30, 2183-2189.
25. Burris,H.A. et al. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol., 29, 398-405.
26. Ingelman-Sundberg,M. (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci., 25, 193-200.
27. Olive,K.P. et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 324, 1457-1461.
28. Wilson,W.R. et al. (2011) Targeting hypoxia in cancer therapy. Nat. Rev. Cancer, 11, 393-410.
29. Wang,R. et al. (2011) Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr. Med. Chem., 18, 3168-3189.
30. Kartner,N. et al. (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science, 221, 1285-1288.
31. Chen,C.J. et al. (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrugresistant human cells. Cell, 47, 381-389.
32. Cole,S.P. et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654.
33. Leith,C.P. et al. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94, 1086-1099.
34. Trock,B.J. et al. (1997) Multidrug resistance in breast cancer: a metaanalysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst., 89, 917-931.
35. Shen,D.W. et al. (2000) Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J. Cell. Physiol., 183, 108-116.
36. Shen,D. et al. (1998) Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res., 58, 268-275.
37. Hayes,J.D. et al. (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol., 30, 445-600.
38. Robert,J. et al. (2003) Multidrug resistance reversal agents. J. Med. Chem., 46, 4805-4817.
39. Belpomme,D. et al. (2000) Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol., 11, 1471-1476.
40. Warner,E. et al. (1998) Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin. Cancer Res., 4, 1451-1457.
41. Rowinsky,E.K. et al. (1994) Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12, 2193-2203.
42. Wishart,G.C. et al. (1994) Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. Clin. Oncol., 12, 1771-1777.
43. Tsimberidou,A. et al. (2003) Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer, 97, 1481-1487.
44. List,A.F. et al. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood, 98, 3212-3220.
45. Gruber,A. et al. (2003) A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk. Res., 27, 323-328.
46. Szakács,G. et al. (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 5, 219-234.
47. Hindenburg,A.A. et al. (1989) Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and-resistant HL-60 cells. Cancer Res., 49, 4607-4614.
48. Altan,N. et al. (1998) Defective acidification in human breast tumor cells and implications for chemotherapy. J. Exp. Med., 187, 1583-1598.
49. Tell,G. et al. (2010) Targeting DNA repair proteins for cancer treatment. Cell. Mol. Life Sci., 67, 3569-3572.
50. Hegi,M.E. et al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res., 10, 1871-1874.
51. Agnihotri,S. et al. (2012) Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J. Clin. Invest., 122, 253-266.
52. Knappskog,S. et al. (2012) Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res., 14, R47.
53. Adams,J.M. et al. (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26, 1324-1337.
54. Happo,L. et al. (2010) Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood, 116, 5256-5267.
55. Fulda,S. et al. (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov., 11, 109-124.
56. Ni Chonghaile,T. et al. (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene, 27 (suppl. 1), S149-S157.
57. Kutuk,O. et al. (2008) Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res., 68, 7985-7994.
58. Weinstein,I.B. (2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science, 297, 63-64.
59. Weinstein,I.B. et al. (2008) Oncogene addiction. Cancer Res., 68, 3077-3080.
60. Weinstein,I.B. et al. (2006) Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol., 3, 448-457.
61. Sharma,S.V. et al. (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev., 21, 3214-3231.
62. Casaletto,J.B. et al. (2012) Spatial regulation of receptor tyrosine kinases in development and cancer. Nat. Rev. Cancer, 12, 387-400.
63. Mellinghoff,I.K. et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med., 353, 2012-2024.
64. Nielsen,D.L. et al. (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast, 22, 1-12.
65. Gherardi,E. et al. (2012) Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer, 12, 89-103.
66. Weigelt,B. et al. (2012) Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol., 2, 109.
67. Cloughesy,T.F. et al. (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med., 5, e8.
68. Flaherty,K.T. et al. (2012) From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer, 12, 349-361.
69. Masui,K. et al. (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol. Appl. Neurobiol., 38, 271-291.
70. Vivanco,I. et al. (2012) Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov., 2, 458-471.
71. Tsao,A.S. et al. (2012) Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J. Thorac. Oncol., 7, 1645-1652.
72. Kobayashi,S. et al. (2005) EGFR mutation and resistance of non-smallcell lung cancer to gefitinib. N. Engl. J. Med., 352, 786-792.
73. Kwak,E.L. et al. (2010) Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N. Engl. J. Med., 363, 1693-1703.
74. Zhang,X. et al. (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int. J. Med. Sci., 5, 209-217.
75. Sequist,L.V. et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3, 75ra26.
76. Ng,K.P. et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med., 18, 521-528.
77. Jänne,P.A. et al. (2012) Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J. Clin. Oncol., 30, 2063-2069.
78. Heinrich,M.C. et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol., 21, 4342-4349.
79. Antonescu,C.R. (2011) The GIST paradigm: lessons for other kinasedriven cancers. J. Pathol., 223, 251-261.
80. Di Nicolantonio,F. et al. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest., 120, 2858-2866.
81. Prahallad,A. et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 483, 100-103.
82. Fong,P.C. et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 361, 123-134.
83. Sun,W. (2012) Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J. Hematol. Oncol., 5, 63.
84. Packer,L.M. et al. (2011) Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell, 20, 715-727.
85. Druker,B.J. et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344, 1031-1037.
86. Kantarjian,H.M. et al. (2010) Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer, 116, 1419-1430.
87. O'Hare,T. et al. (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer, 12, 513-526.
88. Mahon,F.X. et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96, 1070-1079.
89. Esposito,N. et al. (2011) SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood, 118, 3634-3644.
90. Burchert,A. et al. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia, 19, 1774-1782.
91. Apperley,J.F. (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol., 8, 1018-1029.
92. O'Hare,T. et al. (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin. Cancer Res., 17, 212-221.
93. Chen,L. et al. (2007) Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr. Opin. Drug Discov. Devel., 10, 403-412.
94. Janku,F. et al. (2013) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in earlyphase clinical trials. Cancer Res., 73, 276-284.
95. Faber,A.C. et al. (2011) BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov., 1, 352-365.
96. Ibrahim,Y.H. et al. (2012) PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov., 2, 1036-1047.
97. Lai,Y.L. et al. (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann. Surg. Oncol., 15, 1064-1069.
98. Janku,F. et al. (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol., 30, 777-782.
99. Karamouzis,M.V. et al. (2009) Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol., 10, 709-717.
100. Nghiemphu,P.L. et al. (2012) A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. J. Neurooncol., 110, 245-250.
101. Mellinghoff,I.K. et al. (2007) PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res., 13(2 Pt 1), 378-381.
102. de Vries,N.A. et al. (2012) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest. New Drugs, 30, 443-449.
103. Weller,M. (2011) Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med. Wkly., 141, w13210.
104. Fenton,T.R. et al. (2012) Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc. Natl. Acad. Sci. U.S.A., 109, 14164-14169.
105. Elfiky,A.A. et al. (2012) Novel molecular targets for the therapy of renal cell carcinoma. Discov. Med., 13, 461-471.
106. Mahalingam,D. et al. (2010) Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res., 16, 141-153.
107. Hainsworth,J.D. et al. (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol., 28, 2131-2136.
108. Ghamande,S.A. et al. (2008) A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol. Oncol., 111, 89-94.
109. Janku,F. et al. (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther., 10, 558-565.
110. Slomovitz, B.M. et al. (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin. Cancer Res., 18, 5856-5864.
111. Chapman,P.B. et al.; BRIM-3 Study Group. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 364, 2507-2516.
112. Nazarian,R. et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 468, 973-977.
113. Johannessen,C.M. et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468, 968-972.
114. Villanueva,J. et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 18, 683-695.
115. Paraiso,K.H. et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res., 71, 2750-2760.
116. Emery,C.M. et al. (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U.S.A., 106, 20411-20416.
117. Poulikakos,P.I. et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480, 387-390.
118. Shi,H. et al. (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun., 3, 724.
119. Greger,J.G. et al. (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther., 11, 909-920.
120. Flaherty,K.T. et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med., 367, 1694-1703.
121. Roschewski,M. et al. (2012) Diffuse large B cell lymphoma: molecular targeted therapy. Int. J. Hematol., 96, 552-561.
122. Friedberg,J.W. et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 115, 2578-2585.
123. Robertson,M.J. et al. (2007) Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol., 25, 1741-1746.
124. Foon,K.A. et al. (2012) Novel therapies for aggressive B-cell lymphoma. Adv. Hematol., 2012, 302570.
125. Scott,A.M. et al. (2012) Antibody therapy of cancer. Nat. Rev. Cancer, 12, 278-287.
126. Pardoll,D.M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 12, 252-264.
127. Baselga,J. et al.; CLEOPATRA Study Group. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med., 366, 109-119.
128. Blackwell, K.L., et al. (2012) Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. ASCO Meeting Abstracts, 30, LBA1.
129. Neyns,B. et al. (2009) Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann. Oncol., 20, 1596-1603.
130. Varker,K.A. et al. (2007) A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol., 14, 2367-2376.
131. Hodi,F.S. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 363, 711-723.
132. Robert,C. et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med., 364, 2517-2526.
133. Coiffier,B. et al. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 2040-2045.
134. Vanneman,M. et al. (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer, 12, 237-251.
135. Tanaka,K. et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov., 1, 524-538.
136. Thomas,H.E. et al. (2012) mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci. Transl. Med., 4, 139ra84.
137. Haas-Kogan,D.A. et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst., 97, 880-887.
138. Kreisl,T.N. et al. (2009) A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol., 92, 99-105.
139. Reardon,D.A. et al. (2006) Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res., 12(3 Pt 1), 860-868.
140. Stommel,J.M. et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318, 287-290.
141. Huang,P.H. et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. U.S.A., 104, 12867-12872.
142. Chandarlapaty,S. et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell, 19, 58-71.
143. Gazdar,A.F. (2009) Activating and resistance mutations of EGFR in nonsmall-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28 (suppl. 1), S24-S31.
144. Balak,M.N. et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res., 12, 6494-6501.
145. Miller,V.A. et al. (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol., 13, 528-538.
146. Zhou,W. et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 462, 1070-1074.
147. Saal,L.H. et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res., 65, 2554-2559.
148. Berns,K. et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell, 12, 395-402.
149. De Roock,W. et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol., 11, 753-762.
150. Chang,S.M. et al.; North American Brain Tumor Consortium and the National Cancer Institute. (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs, 23, 357-361.
151. Galanis,E. et al.; North Central Cancer Treatment Group. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol., 23, 5294-5304.
152. Reardon,D.A. et al. (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol., 96, 219-230.
153. Fan,Q.W. et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 9, 341-349.
154. Carracedo,A. et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest., 118, 3065-3074.
155. Thoreen,C.C. et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem., 284, 8023-8032.
156. Rodrik-Outmezguine,V.S. et al. (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov., 1, 248-259.
157. Trumpp,A. et al. (2008) Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat. Clin. Pract. Oncol., 5, 337-347.
158. Bao,S. et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
159. Sharma,S.V. et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141, 69-80.
160. Dedes,K.J. et al. (2010) PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med., 2, 53ra75.
161. Turner,N.C. et al. (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol., 13, e178-e185.
162. Yap,T.A. et al. (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med., 4, 127ps10.
163. Gerlinger,M. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med., 366, 883-892.
164. Shah,S.P. et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 486, 395-399.
165. Christensen,J.G. et al. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther., 6(12 Pt 1), 3314-3322.
166. Kentsis,A. et al. (2012) Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat. Med., 18, 1118-1122.
167. Camidge,D.R. et al. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol., 13, 1011-1019.
168. Butrynski,J.E. et al. (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med., 363, 1727-1733.
169. Costa,D.B. et al. (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol., 29, e443-e445.
170. Choi,Y.L. et al.; ALK Lung Cancer Study Group. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med., 363, 1734-1739.
171. Sasaki,T. et al. (2010) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res., 70, 10038-10043.
172. Heuckmann,J.M. et al. (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res., 17, 7394-7401.
173. Yamada,T. et al. (2012) Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin. Cancer Res., 18, 3592-3602.
174. Berry,T. et al. (2012) The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell, 22, 117-130.
175. Byers,L.A. et al. (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res., 19, 279-290.
176. Zhang,Z. et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet., 44, 852-860.
177. Gasparini,G. et al. (2007) Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res. Treat., 101, 355-365.
178. Chapuis,N. et al. (2010) Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia, 24, 1686-1699.
179. Zhu,J. et al. (2007) RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell, 12, 23-35.
180. Zhang,Y. et al. (2013) Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer, 119, 115-125.
181. Martinelli,G. et al. (1998) Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy. Haematologica, 83, 985-988.
182. Sanz,M.A. et al.; PETHEMA and HOVON Groups. (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 115, 5137-5146.
183. Reya,T. et al. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111.
184. Wilson,W.H. et al. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol., 11, 1149-1159.
185. Rudin,C.M. et al. (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res., 18, 3163-3169.
186. Baggstrom,M.Q. et al.; Mayo Phase 2 Consortium; California Consortium. (2011) A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J. Thorac. Oncol., 6, 1757-1760.
187. Sonpavde,G. et al. (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann. Oncol., 23, 1803-1808.
188. Mathieu,V. et al. (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia, 10, 1383-1392.
189. Volk,L.D. et al. (2008) Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia, 10, 613-623.
190. Kerbel,R.S. (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science, 312, 1171-1175.
191. Claes,A. et al. (2008) Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol. Cancer Ther., 7, 71-78.
192. Shepherd,F.A. et al.; National Cancer Institute of Canada Clinical Trials Group. (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 353, 123-132.
193. Reck,M. et al. (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J. Thorac. Oncol., 5, 1616-1622.
194. Giaccone,G. et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol., 22, 777-784.
195. Herbst,R.S. et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol., 22, 785-794.
196. Herbst,R.S. et al.; TRIBUTE Investigator Group. (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol., 23, 5892-5899.
197. Gatzemeier,U. et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol., 25, 1545-1552.
198. Davies,A.M. et al. (2006) Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin. Lung Cancer, 7, 385-388.
199. Li,T. et al. (2007) Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin. Cancer Res., 13, 3413-3422.
200. Solit,D.B. et al. (2005) Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin. Cancer Res., 11, 1983-1989.
201. Mahaffey,C.M. et al. (2007) Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin. Lung Cancer, 8, 548-553.
202. Mok,T.S. et al. (2009) Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol., 27, 5080-5087.
203. Gridelli,C. et al. (2012) First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J. Clin. Oncol., 30, 3002-3011.
204. Verhaak,R.G. et al.; Cancer Genome Atlas Research Network. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110.